Bluebird Bio withdrew its gene therapies from all of Europe because no country would pay the price, stranding patients with no alternative curative option

Bluebird Bio developed two gene therapies -- Zynteglo for transfusion-dependent beta-thalassemia and Skysona (eli-cel) for cerebral adrenoleukodystrophy (CALD) -- that represented genuine one-time cures for devastating conditions. Both received European marketing authorization. Both demonstrated clinical efficacy. And both were withdrawn from the entire European market by early 2022 because Bluebird could not reach reimbursement agreements with European payers. The company's CEO called the European pricing situation "untenable" and described the market as "broken." Bluebird closed down all European operations to focus exclusively on the US. For European patients with transfusion-dependent beta-thalassemia -- who face lifelong biweekly blood transfusions and iron chelation therapy, with progressive organ damage from iron overload -- Zynteglo's withdrawal meant the loss of their only shot at a transfusion-free life. For children with CALD -- a condition where the myelin sheath of the brain is progressively destroyed, leading to loss of speech, vision, hearing, and motor function -- Skysona's withdrawal meant the only alternative was allogeneic stem cell transplant, which requires a matched donor and carries significant mortality risk. These patients didn't lose access because the drug failed. They lost access because the financial negotiation between a company and national health systems failed. The situation has only gotten worse. In the US, the FDA restricted Skysona's use in 2024 after reports of blood cancer in some treated patients, limiting it to patients without an available matched donor. Skysona recorded zero sales in the first three months of 2025. Meanwhile, Bluebird Bio itself faced severe financial difficulties, with layoffs in 2024 and ongoing cash flow struggles. The structural problem is that the gene therapy business model is fundamentally fragile: massive upfront R&D costs, tiny patient populations, uncertain long-term safety profiles, and payers who are structurally unable to absorb seven-figure per-patient costs. When the company developing your only treatment goes bankrupt or exits your market, there is no backup plan. The drug doesn't transfer to a generic manufacturer. The manufacturing process is too specialized. You simply go without.